文献速递淋巴瘤白血病MDS 与骨髓增殖性肿瘤

153115例血液系统恶性肿瘤患者分析细化家族性风险谱

Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk.
PubMed 文献 · Blood · 2019-08-08

多数血液系统恶性肿瘤同类型肿瘤的家族相对风险升高,最高见于混合细胞型霍奇金淋巴瘤(SIR 16.7)、淋巴浆细胞淋巴瘤(SIR 15.8)和套细胞淋巴瘤(SIR 13.3)。研究还发现多效性关联,如慢性淋巴细胞白血病与其他B细胞肿瘤及骨髓增殖性肿瘤的家族风险升高相关。

要点

  • 多数血液系统恶性肿瘤患者一级亲属同类型肿瘤的家族相对风险升高。
  • 混合细胞型霍奇金淋巴瘤、淋巴浆细胞淋巴瘤和套细胞淋巴瘤的家族相对风险最高。
  • 慢性淋巴细胞白血病与其他B细胞肿瘤及骨髓增殖性肿瘤存在家族风险关联。

核心结论

  • 多数血液系统恶性肿瘤在同类型肿瘤中显示家族相对风险升高,并存在多效性关联,提示共享病因因素。

主要发现

  • 混合细胞型霍奇金淋巴瘤的SIR为16.7,淋巴浆细胞淋巴瘤为15.8,套细胞淋巴瘤为13.3。
  • 慢性淋巴细胞白血病与其他B细胞肿瘤及骨髓增殖性肿瘤的家族风险升高相关。

临床怎么用

  • 研究数据有助于识别血液系统恶性肿瘤高风险个体,并为未来基因发现研究提供信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Estimating familial cancer risks is clinically important in being able to discriminate between individuals in the population at differing risk for malignancy. To gain insight into the familial risk for the different hematological malignancies and their possible inter-relationship, we analyzed data on more than 16 million individuals from the Swedish Family-Cancer Database. After identifying 153 115 patients diagnosed with a primary hematological malignancy, we quantified familial relative risks (FRRs) by calculating standardized incident ratios (SIRs) in 391 131 of their first-degree relatives. The majority of hematological malignancies showed increased FRRs for the same tumor type, with the highest FRRs being observed for mixed cellularity Hodgkin lymphoma (SIR, 16.7), lymphoplasmacytic lymphoma (SIR, 15.8), and mantle cell lymphoma (SIR, 13.3). There was evidence for pleiotropic relationships; notably, chronic lymphocytic leukemia was associated with an elevated familial risk for other B-cell tumors and myeloproliferative neoplasms. Collectively, these data provide evidence for shared etiological factors for many hematological malignancies and provide information for identifying individuals at increased risk, as well as informing future gene discovery initiatives.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sud A, Chattopadhyay S, Thomsen H, et al. Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. Blood. 2019. PMID: 31395603. doi:10.1182/blood.2019001362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。